Inclusion Criteria:  Written informed consent Advanced (metastatic or unresectable) KRAS G12C mutant solid tumors, with failure or absence of standard treatment Subject must be ≥18 years Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. Subjects with life expectancy ≥3 months. Subjects must have at least one measurable lesion as defined by RECIST v1.1. There was no serious organ dysfunction in the screening stage Male or female subjects of reproductive age agree to use adequate contraception  Exclusion Criteria:  History of intestinal disease or major gastric surgery or inability to swallow oral medications Other active cancer Previously treated with KRAS G12C inhibitor Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV) Impaired heart function or clinically significant heart disease Pregnant or breast-feeding Previous allogeneic bone marrow transplant or organ transplant Intended study subjects who were unable to abstain from alcohol during medication Other unqualified conditions judged by the investigators